tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Nerve Degeneration D009410 53 associated lipids
Nervous System Diseases D009422 37 associated lipids
Neuritis D009443 4 associated lipids
Neurodermatitis D009450 1 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Neutropenia D009503 15 associated lipids
Nocardia Infections D009617 6 associated lipids
Obesity D009765 29 associated lipids
Oliguria D009846 2 associated lipids
Opportunistic Infections D009894 8 associated lipids
Optic Neuritis D009902 1 associated lipids
Orchitis D009920 1 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Osteomalacia D010018 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Osteoporosis D010024 12 associated lipids
Ovarian Cysts D010048 4 associated lipids
Pain D010146 64 associated lipids
Pain, Intractable D010148 4 associated lipids
Pancreatic Fistula D010185 2 associated lipids
Pancytopenia D010198 6 associated lipids
Paraproteinemias D010265 2 associated lipids
Paresis D010291 2 associated lipids
Parkinson Disease D010300 53 associated lipids
Paronychia D010304 3 associated lipids
Parotitis D010309 4 associated lipids
Pemphigoid, Benign Mucous Membrane D010390 4 associated lipids
Pemphigoid, Bullous D010391 8 associated lipids
Pemphigus D010392 3 associated lipids
Peptic Ulcer D010437 19 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Perceptual Disorders D010468 3 associated lipids
Pericarditis D010493 6 associated lipids
Periodontal Pocket D010514 9 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Peritoneal Neoplasms D010534 16 associated lipids
Pharyngitis D010612 2 associated lipids
Pityriasis D010915 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Postoperative Complications D011183 5 associated lipids
Poxviridae Infections D011213 1 associated lipids
Precancerous Conditions D011230 48 associated lipids
Pregnancy Complications D011248 19 associated lipids
Priapism D011317 1 associated lipids
Proteinuria D011507 30 associated lipids
Prurigo D011536 4 associated lipids
Pruritus Ani D011538 2 associated lipids
Pruritus Vulvae D011539 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Psoriasis D011565 47 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Pterygium D011625 3 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Rectal Diseases D012002 1 associated lipids
Rectal Fistula D012003 2 associated lipids
Red-Cell Aplasia, Pure D012010 4 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Respiration Disorders D012120 5 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Respiratory Tract Neoplasms D012142 2 associated lipids
Retinoblastoma D012175 12 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Rosacea D012393 13 associated lipids
Rotavirus Infections D012400 1 associated lipids
Rupture D012421 2 associated lipids
Sarcoidosis D012507 13 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
Osteosarcoma D012516 50 associated lipids
Scalp Dermatoses D012536 11 associated lipids
Sclerosis D012598 5 associated lipids
Dermatitis, Seborrheic D012628 10 associated lipids
Seizures D012640 87 associated lipids
Shock D012769 11 associated lipids
Shock, Septic D012772 11 associated lipids
Sinusitis D012852 9 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Skin Neoplasms D012878 12 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Stomach Ulcer D013276 75 associated lipids
Stomatitis D013280 14 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Tachycardia D013610 7 associated lipids
Telangiectasis D013684 2 associated lipids
Testicular Diseases D013733 15 associated lipids
Thinness D013851 11 associated lipids
Thrombocytopenia D013921 15 associated lipids
Thrombophlebitis D013924 6 associated lipids
Thrombosis D013927 49 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Thyroid Diseases D013959 8 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Tinea D014005 5 associated lipids
Tinea Capitis D014006 1 associated lipids
Tongue Diseases D014060 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Vincenti F A decade of progress in kidney transplantation. 2004 Transplantation pmid:15201687
Pascual J et al. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. 2006 Transplantation pmid:16861942
Asberg A et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. 2006 Transplantation pmid:16861943
Pfitzmann R et al. Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. 2003 Transplantation pmid:12865798
Todo S et al. Abdominal multivisceral transplantation. 1995 Transplantation pmid:7530873
Drachenberg CB et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. 1999 Transplantation pmid:10459544
Briggs D et al. Effects of immediate switch from cyclosporine microemulsion to tacrolimus at first acute rejection in renal allograft recipients. 2003 Transplantation pmid:12829912
Vu MD et al. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. 1997 Transplantation pmid:9422432
Chaftari AM et al. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. 2012 Transplantation pmid:22814329
Reese JC et al. The effect of FK506 on canine bile flow. 1993 Transplantation pmid:7504342
Cox KL et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. 1995 Transplantation pmid:7533344
McDiarmid SV et al. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial. 1995 Transplantation pmid:7533345
Selzner N et al. Conversion from cyclosporine to FK506 in adult liver transplant recipients: a combined North American and European experience. 2001 Transplantation pmid:11579301
Savoldo B et al. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. 2001 Transplantation pmid:11579304
Fisher NC et al. Chronic renal failure following liver transplantation: a retrospective analysis. 1998 Transplantation pmid:9679823
Sanchez-Campos S et al. Cholestasis and alterations of glutathione metabolism induced by tacrolimus (FK506) in the rat. 1998 Transplantation pmid:9679826
Shao X et al. Tacrolimus-associated ischemic optic neuropathy and posterior reversible encephalopathy syndrome after small bowel transplantation. 2012 Transplantation pmid:23128973
Tsuchiya T et al. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus. 2013 Transplantation pmid:23792649
Newell KA et al. Treatment with either anti-CD4 or anti-CD8 monoclonal antibodies blocks alphabeta T cell-mediated rejection of intestinal allografts in mice. 1997 Transplantation pmid:9381541
Iyengar AR et al. Striking augmentation of hematopoietic cell chimerism in noncytoablated allogeneic bone marrow recipients by FLT3 ligand and tacrolimus. 1997 Transplantation pmid:9158008
Størset E et al. Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study. 2015 Transplantation pmid:25886918
Hill CC et al. Penile prosthesis surgery in the immunosuppressed patient. 1993 Transplantation pmid:7692633
Yanchar NL et al. Tacrolimus (FK506)--its effects on intestinal glucose transport. 1996 Transplantation pmid:8610392
Hariharan S et al. Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. 1996 Transplantation pmid:8610411
Reyes J et al. Expressive dysphasia possibly related to FK506 in two liver transplant recipients. 1990 Transplantation pmid:1701571
Bronster DJ et al. Tacrolimus-associated mutism after orthotopic liver transplantation. 2000 Transplantation pmid:11014653
Mittal SK et al. Increased interleukin-10 production without expansion of CD4+CD25+ T-regulatory cells in early stable renal transplant patients on calcineurin inhibitors. 2009 Transplantation pmid:19667950
Kihm LP et al. Acute effects of calcineurin inhibitors on kidney allograft microperfusion visualized by contrast-enhanced sonography. 2012 Transplantation pmid:22470107
Hoogtanders K et al. Dried blood spot measurement of tacrolimus is promising for patient monitoring. 2007 Transplantation pmid:17264824
Pérgola PE et al. Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone. 2001 Transplantation pmid:11349738
Xie Y et al. Delayed Donor Bone Marrow Infusion Induces Liver Transplant Tolerance. 2017 Transplantation pmid:28187014
Hooper DK et al. Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. 2012 Transplantation pmid:22491658
Sarwal MM et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. 2003 Transplantation pmid:14627912
Ciancio G et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. 2008 Transplantation pmid:18622280
Vignali D et al. IL-7 Mediated Homeostatic Expansion of Human CD4+CD25+FOXP3+ Regulatory T Cells After Depletion With Anti-CD25 Monoclonal Antibody. 2016 Transplantation pmid:27306531
Woodle ES et al. FK506: inhibition of humoral mechanisms of hepatic allograft rejection. 1992 Transplantation pmid:1379749
Chakrabarti P et al. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. 2000 Transplantation pmid:11003353
de Fijter JW Tacrolimus dosing in mycophenolate-treated patients--can we get away with less? 2011 Transplantation pmid:21654351
Nankivell BJ et al. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras. 2016 Transplantation pmid:27306529
Ko S et al. The enhanced immunosuppressive efficacy of newly developed liposomal FK506 in canine liver transplantation. 1995 Transplantation pmid:7539553
Reich DJ et al. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. 2005 Transplantation pmid:16003228
Paterson DL et al. Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. 1998 Transplantation pmid:9753337
Guthery SL et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. 2003 Transplantation pmid:12698085
Guasch A et al. Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. 2010 Transplantation pmid:20811320
Azzola A et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. 2004 Transplantation pmid:14742993
Hoerning A et al. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity. 2015 Transplantation pmid:25099702
Yilmaz MI et al. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. 2005 Transplantation pmid:16378057
Zhang W et al. Isoglycyrrhizinate Magnesium Enhances Hepatoprotective Effect of FK506 on Ischemia-Reperfusion Injury Through HMGB1 Inhibition in a Rat Model of Liver Transplantation. 2017 Transplantation pmid:28885495
Langrehr JM et al. Clinical course, morphology, and treatment of chronically rejecting small bowel allografts. 1993 Transplantation pmid:7679526
Guitard J et al. Predictive factors for anemia six and twelve months after orthotopic liver transplantation. 2006 Transplantation pmid:16770241